Clinical trials: Symptoms, Behavioral
Pulmonary Disease, Chronic Obstructive
TARA Working Prototype Engagement Evaluation: Feasibility Study
TARA is a Digital Behaviour Change Intervention (DBCI) for individuals with Chronic Obstructive Pulmonary Disease (COPD)(IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology.
- Trial name
- NCT04085302
- Testing
- Digital Behaviour Change Intervention
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Depression
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01072929
- Testing
- Armodafinil
- Where
- 40 sites in United States
- Volunteers
- 433 people
- Sponsor
- Cephalon
Major Depressive Disorder
Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1.
- Trial name
- NCT00810069
- Testing
- Duloxetine Hydrochloride, Escitalopram
- Where
- 60 sites in Denmark, France and 9 more
- Volunteers
- 840 people
- Sponsor
- Eli Lilly and Company
Depression
MYnd Analytics Directed Therapy in Depression
The MYnd Analytics PEER Online strategy utilizes EEG diagnostics to direct patients with psychiatric illnesses to the best medication treatments.
- Trial name
- NCT03328052
- Testing
- MYnd Analytics PEER Online directed antidepressant therapy, Conventional antidepressant therapy
- Where
- 16 sites in United States
- Volunteers
- 600 people
- Sponsor
- Cota Inc.
Depression
Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl
This is a study to determine the percentage of patients with depression who are treated with extended-release venlafaxine HCl (U.S.
- Trial name
- NCT00788944
- Testing
- blood draw
- Where
- 52 sites in United States
- Volunteers
- 971 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158533
- Testing
- High Dose ALKS 5461, Low Dose ALKS 5461
- Where
- 49 sites in United States, Australia and 1 more
- Volunteers
- 385 people
- Sponsor
- Alkermes, Inc.
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.
- Trial name
- AB06006 (NCT00814073)
- Testing
- Masitinib, Best Supportive Care
- Where
- 24 sites in United States, France
- Volunteers
- 135 people
- Sponsor
- AB Science
Depression, Depression Moderate
Kintsugi Voice Device Pilot Study
A prospective, single arm, non-randomized, pilot clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made…
- Conditions
- Depression, Depression Moderate, Depression Severe, Depression Mild
- Trial name
- NCT06374056
- Testing
- Kintsugi Voice Device
- Where
- United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Airway Obstruction, Sedation Complication
Evaluation of Medical Device for Airway Patency During Sedation (SW01-2022)
The goal of this four-part preclinical [I-II] and clinical [III-IV] trial is to compare, with randomised crossover study design [I-IV], a new medical airway device with standard procedure (biteblock or no device) for upper airway…
- Conditions
- Airway Obstruction, Sedation Complication, Safety Issues, Patient Satisfaction
- Trial name
- NCT05708651
- Testing
- Investigational device [I-IV], Comparator [I-IV]
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Stairway Medical AB
Unipolar Depression, Major Depressive Disorder (MDD)
Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach.
- Conditions
- Unipolar Depression, Major Depressive Disorder (MDD), Depression
- Trial name
- EMC2FR (NCT06860165)
- Where
- 2 sites in France
- Volunteers
- 98 people
- Sponsor
- Emobot
Fatigue, Stress
The U.K. Embryologist Fatigue Study
The purpose of the study is to determine physical and mental health issues of U.K. embryologists related to their occupational characteristics, and how workplace fatigue and burnout may affect their quality of life, cynicism…
- Conditions
- Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain
- Trial name
- FUSE-UK (NCT05708963)
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- TMRW Life Sciences
Depression, Anxiety, Trauma
Validation of myStrength's Macropersonalization Engine
This is a study to validate myStrength's macropersonalization algorithm. Specifically, the study seeks to answer: Does myStrength's macropersonalization algorithm match what a clinician would offer as a diagnosis following an…
- Trial name
- PAG-Macro (NCT05417178)
- Testing
- myStrength Macropersonalization Enginge
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Teladoc Health
Post-Concussion Symptoms, Insomnia
Neurotechnology Following Traumatic Brain Injury
This two-part study seeks to improve symptoms such as pain and sleep problems after concussion, or mild traumatic brain injury (mTBI).
- Conditions
- Post-Concussion Symptoms, Insomnia, Pain, Chronic, Depressive Symptoms
- Trial name
- Cereset (NCT03649958)
- Testing
- HIRREM-SOP or Cereset, Cereset 2x
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Brain State Technologies, LLC
Inflammation, Oxidative Stress
Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking
This is a cross-sectional 3-group study with subjects enrolled and matched by region (Asia, Europe), age, sex, and average daily product consumption over the last 2 years as self-reported.
- Conditions
- Inflammation, Oxidative Stress, Smoking, Smoking Abstinence
- Trial name
- NCT05385055
- Testing
- THS use, Cigarette smoking, Smoking abstinence
- Where
- 37 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 974 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Long COVID
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long…
- Trial name
- NCT07627815
- Testing
- Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations
- Where
- 4 sites in Canada
- Volunteers
- 82 people
- Sponsor
- ParagonClinicals Inc.
Attention Difficulties
Guayusa: The Effect of an Herbal Extract on Alertness and Mental Fatigue
The primary objective of this randomized, double-blind, placebo-controlled, cross-over study is to assess the acute effects of a novel ingredient, guayusa on alertness and mental fatigue compared to a placebo.
- Trial name
- NCT05530915
- Testing
- Gel capsule
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Stress, Psychological, Healthy
A Study to Assess the Safety and Efficacy of Probiotic to Modulate Psychological Stress
The purpose of this clinical trial is to determine whether Probiotic can modulate the psychological stress experienced by healthy medical, dental and health science students preparing for university/institute of technology…
- Trial name
- NCT04125810
- Testing
- Probiotic
- Where
- 7 sites in Ireland, United Kingdom
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Danisco
Treatment-resistant Depression
A Trial of GH001 in Patients With Treatment-resistant Depression
The aim of this randomized, double-blind, placebo-controlled, phase 2b clinical trial is to investigate the safety and efficacy of GH001 (containing mebufotenin [5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT]) in patients with…
- Trial name
- NCT05800860
- Testing
- GH001
- Where
- 11 sites in Czechia, Germany and 4 more
- Volunteers
- 81 people
- Sponsor
- GH Research Ireland Limited
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.